NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Tarsus reported FY2025 XDEMVY net product sales of $451.4M, up more than 150% year over year.
Tarsus reported full-year 2025 XDEMVY net product sales of $451.4M, up more than 150% YoY, with peak sales potential guided above $2B. The company advanced Phase 2 trials for TP-04 in ocular rosacea and plans a Lyme disease prevention study for TP-05. Commercial momentum for XDEMVY remains the primary revenue driver.
- FY2025 XDEMVY sales $451.4M (+150%+ YoY).
- Peak sales potential guided above $2B.
- Phase 2 TP-04 ocular rosacea trial initiated.
- TP-05 Lyme prevention Phase 2 planned.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$451M
Forward guidance
Commercial focus on XDEMVY growth and lifecycle extensions via TP-04 and TP-05 programs.
Tailwinds
- Rapid XDEMVY uptake supports blockbuster trajectory.
- Pipeline expansion into adjacent eye-care indications.
- Strong specialist community adoption.
Headwinds
- Single-product concentration on XDEMVY.
- Competitive demodex and eye-care therapies emerging.
- Clinical trial risks for pipeline assets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro